Ann: Agreement with MD Anderson for Phase 1B CHM 0201 AML study, page-14

House Question Time 14 September 2023 - YouTube

from 15:37 to 19:12


plus the Peter Mac facility

Expanded cell and gene therapy manufacturing facility opens at Peter Mac - Peter MacCallum Cancer Centre

"....production capacity of up to 2,000 patient doses per year. "


Car-T, in that case blood cancer CAR-T reached the parliament and interesting that some movement finally is on its way.

Peter Mac is using CAR-T and this is from their website

CAR-T Cell therapy - Peter MacCallum Cancer Centre

We have approval to use CAR-T cell therapy in Australia for the following diseases:

• B-cell acute lymphoblastic leukaemia (ALL)
• Adult diffuse large B-cell lymphoma (DLBCL)
• Mantle cell lymphoma (MCL)
• Multiple Myeloma

Should CAR-T finally start making more headlines in the main stream media then the ASX will sooner or later pick it up. At this stage CHM is the only ASX listed company with clinical trials. That would make CHM top of the punters list, not to mention the almost ZERO valuation. Next in line IMU with its Azer-Cel registrational trial soon to be announced. Looking at some of the H2 stock valuations and what they actually have achieved then the sky won't be the limit.

Time to get set for the run. But wait a minute, not yet, still a few to get filled at 3.1c.

GLTA